Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXSM NYSE:BHC NASDAQ:JAZZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXSMAxsome Therapeutics$127.06-2.1%$120.78$75.56▼$139.13$6.47B0.52452,822 shs294,235 shsBHCBausch Health Cos$6.38+2.2%$6.88$4.25▼$9.85$2.31B0.431.44 million shs1.62 million shsJAZZJazz Pharmaceuticals$138.18-0.2%$130.03$95.49▼$148.06$8.40B0.28684,987 shs531,030 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXSMAxsome Therapeutics-1.27%+0.11%+10.41%+23.58%+40.40%BHCBausch Health Cos+1.53%+3.40%-8.57%-7.90%-23.01%JAZZJazz Pharmaceuticals+0.74%+2.00%+6.41%+17.38%+22.48%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXSMAxsome Therapeutics$127.06-2.1%$120.78$75.56▼$139.13$6.47B0.52452,822 shs294,235 shsBHCBausch Health Cos$6.38+2.2%$6.88$4.25▼$9.85$2.31B0.431.44 million shs1.62 million shsJAZZJazz Pharmaceuticals$138.18-0.2%$130.03$95.49▼$148.06$8.40B0.28684,987 shs531,030 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXSMAxsome Therapeutics-1.27%+0.11%+10.41%+23.58%+40.40%BHCBausch Health Cos+1.53%+3.40%-8.57%-7.90%-23.01%JAZZJazz Pharmaceuticals+0.74%+2.00%+6.41%+17.38%+22.48%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXSMAxsome Therapeutics 3.00Buy$178.2040.25% UpsideBHCBausch Health Cos 2.00Hold$9.0041.18% UpsideJAZZJazz Pharmaceuticals 2.76Moderate Buy$179.8030.12% UpsideCurrent Analyst Ratings BreakdownLatest AXSM, JAZZ, and BHC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/22/2025JAZZJazz PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$170.0010/20/2025JAZZJazz PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$167.00 ➝ $180.0010/20/2025AXSMAxsome TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$191.00 ➝ $194.0010/8/2025AXSMAxsome TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025BHCBausch Health CosWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/8/2025JAZZJazz PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/1/2025AXSMAxsome TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$179.009/30/2025AXSMAxsome TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$179.009/27/2025AXSMAxsome TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025BHCBausch Health CosWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)9/27/2025JAZZJazz PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)(Data available from 10/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXSMAxsome Therapeutics$385.69M16.44N/AN/A$1.18 per share107.68BHCBausch Health Cos$9.63B0.25$7.87 per share0.81($0.89) per share-7.16JAZZJazz Pharmaceuticals$4.07B2.06$30.30 per share4.56$67.72 per share2.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXSMAxsome Therapeutics-$287.22M-$5.07N/A45.06N/A-49.88%-283.22%-33.06%11/3/2025 (Estimated)BHCBausch Health Cos-$46M$0.2624.521.37N/A0.99%-852.36%5.25%10/29/2025 (Estimated)JAZZJazz Pharmaceuticals$560.12M-$6.73N/A7.398.23-9.91%5.02%1.73%11/5/2025 (Estimated)Latest AXSM, JAZZ, and BHC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/5/2025Q3 2025JAZZJazz Pharmaceuticals$5.87N/AN/AN/A$1.11 billionN/A11/3/2025Q3 2025AXSMAxsome Therapeutics-$0.80N/AN/AN/A$162.96 millionN/A10/29/2025Q3 2025BHCBausch Health Cos$1.12N/AN/AN/A$2.61 billionN/A8/5/2025Q2 2025JAZZJazz Pharmaceuticals-$5.61-$8.25-$2.64-$11.74$1.05 billion$1.05 billion8/4/2025Q2 2025AXSMAxsome Therapeutics-$1.00-$0.92+$0.08-$0.97$140.02 million$150.04 million7/30/2025Q2 2025BHCBausch Health Cos$0.97$0.90-$0.07$0.40$2.47 billion$2.57 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAXSMAxsome TherapeuticsN/AN/AN/AN/AN/ABHCBausch Health CosN/AN/AN/AN/AN/AJAZZJazz PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXSMAxsome Therapeutics1.661.571.51BHCBausch Health Cos141.901.310.98JAZZJazz Pharmaceuticals1.171.621.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXSMAxsome Therapeutics81.49%BHCBausch Health Cos78.65%JAZZJazz Pharmaceuticals89.14%Insider OwnershipCompanyInsider OwnershipAXSMAxsome Therapeutics22.30%BHCBausch Health Cos19.97%JAZZJazz Pharmaceuticals4.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXSMAxsome Therapeutics38049.90 million38.77 millionOptionableBHCBausch Health Cos20,700370.81 million296.76 millionOptionableJAZZJazz Pharmaceuticals2,80060.66 million58.05 millionOptionableAXSM, JAZZ, and BHC HeadlinesRecent News About These CompaniesAvadel Settles With Jazz Pharmaceuticals, Gets Acquired By AlkermesOctober 23 at 12:50 PM | seekingalpha.comNo nap gap: Alkermes to sleep market early via $2.1B Avadel buyOctober 23 at 8:26 AM | bioworld.comBVanguard Personalized Indexing Management LLC Decreases Stake in Jazz Pharmaceuticals PLC $JAZZOctober 23 at 3:46 AM | marketbeat.comAlkermes plots $2.1B acquisition of Avadel and its long-acting narcolepsy drug LumryzOctober 22 at 9:11 PM | fiercepharma.comFWells Fargo says Avadel settlemnet adds $5 to Jazz Pharmaceuticals DCFOctober 22 at 9:11 PM | msn.comAvadel, Jazz Pharmaceuticals End Patent Dispute With SettlementOctober 22 at 9:11 PM | marketwatch.comJazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025October 22 at 4:15 PM | prnewswire.com23,900 Shares in Jazz Pharmaceuticals PLC $JAZZ Bought by VIRGINIA RETIREMENT SYSTEMS ET AlOctober 22 at 4:37 AM | marketbeat.comIambic Announces Research Collaboration with Jazz Pharmaceuticals for IAM1363 and Zanidatamab Combination Cohort in HER2-Positive Breast CancerOctober 21 at 11:55 AM | finance.yahoo.comJohn G Ullman & Associates Inc. Sells 3,208 Shares of Jazz Pharmaceuticals PLC $JAZZOctober 19, 2025 | marketbeat.comJazz Pharmaceuticals PLC $JAZZ Shares Purchased by Allianz Asset Management GmbHOctober 19, 2025 | marketbeat.comEnvestnet Portfolio Solutions Inc. Purchases 7,465 Shares of Jazz Pharmaceuticals PLC $JAZZOctober 19, 2025 | marketbeat.comPraxis Precision’s tremor-drug trial succeeds where others have failed. The stock is skyrocketing.October 16, 2025 | msn.comJazz Pharmaceuticals PLC $JAZZ Holdings Lifted by Bayforest Capital LtdOctober 15, 2025 | marketbeat.comBoston Trust Walden Corp Buys 229,885 Shares of Jazz Pharmaceuticals PLC $JAZZOctober 15, 2025 | marketbeat.comCallan Family Office LLC Buys New Position in Jazz Pharmaceuticals PLC $JAZZOctober 14, 2025 | marketbeat.comAssessing Jazz Pharmaceuticals (JAZZ) Valuation Following Strong Recent Share Price MomentumOctober 13, 2025 | finance.yahoo.comQ3 EPS Forecast for Jazz Pharmaceuticals Reduced by AnalystOctober 13, 2025 | marketbeat.comJazz Pharmaceuticals PLC $JAZZ Shares Sold by Meritage Portfolio ManagementOctober 12, 2025 | marketbeat.comJazz Pharmaceuticals PLC $JAZZ Shares Purchased by KLP Kapitalforvaltning ASOctober 12, 2025 | marketbeat.comZacks Research Has Positive Forecast for JAZZ Q2 EarningsOctober 11, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAXSM, JAZZ, and BHC Company DescriptionsAxsome Therapeutics NASDAQ:AXSM$127.06 -2.66 (-2.05%) Closing price 04:00 PM EasternExtended Trading$127.15 +0.09 (+0.07%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Bausch Health Cos NYSE:BHC$6.38 +0.14 (+2.16%) Closing price 03:59 PM EasternExtended Trading$6.30 -0.07 (-1.10%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.Jazz Pharmaceuticals NASDAQ:JAZZ$138.18 -0.34 (-0.25%) Closing price 04:00 PM EasternExtended Trading$138.19 +0.01 (+0.01%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Is Oracle’s AI Rally Over? Wall Street Thinks ORCL Could Hit $400 GM Posts Largest Gain Since the Pandemic: Shares Still Look Cheap 3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
